# CapsoVision, Inc: financial statements, quarterly

CV · Nasdaq · CIK 1378325 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cv.md) · [Financials](/companies/cv/financials.md) · [Filings](/companies/cv/filings.md) · [Insiders](/companies/cv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cv/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [2,843](/filings/0001378325-25-000010.md) | [2,966](/filings/0001378325-25-000040.md) | [3,452 d](/filings/0001378325-26-000010.md) | [2,783](/filings/0001378325-26-000021.md) | [3,315](/filings/0001378325-26-000036.md) | [3,538](/filings/0001378325-25-000040.md) | [3,918 d](/filings/0001378325-26-000010.md) | [2,792](/filings/0001378325-26-000021.md) | [3,643](/filings/0001378325-26-000036.md) |
| Cost of revenue | $k | not reported | [1,251](/filings/0001378325-25-000010.md) | [1,309](/filings/0001378325-25-000040.md) | [1,718 d](/filings/0001378325-26-000010.md) | [1,289](/filings/0001378325-26-000021.md) | [1,504](/filings/0001378325-26-000036.md) | [1,624](/filings/0001378325-25-000040.md) | [1,964 d](/filings/0001378325-26-000010.md) | [1,463](/filings/0001378325-26-000021.md) | [1,772](/filings/0001378325-26-000036.md) |
| Gross profit | $k | not reported | [1,592](/filings/0001378325-25-000010.md) | [1,657](/filings/0001378325-25-000040.md) | [1,734 d](/filings/0001378325-26-000010.md) | [1,494](/filings/0001378325-26-000021.md) | [1,811](/filings/0001378325-26-000036.md) | [1,914](/filings/0001378325-25-000040.md) | [1,954 d](/filings/0001378325-26-000010.md) | [1,329](/filings/0001378325-26-000021.md) | [1,871](/filings/0001378325-26-000036.md) |
| Research and development | $k | not reported | [4,222](/filings/0001378325-25-000010.md) | [4,522](/filings/0001378325-25-000040.md) | [3,116 d](/filings/0001378325-26-000010.md) | [3,107](/filings/0001378325-26-000021.md) | [3,392](/filings/0001378325-26-000036.md) | [6,090](/filings/0001378325-25-000040.md) | [5,721 d](/filings/0001378325-26-000010.md) | [4,435](/filings/0001378325-26-000021.md) | [5,309](/filings/0001378325-26-000036.md) |
| Operating income | $k | not reported | [(5,271)](/filings/0001378325-25-000010.md) | [(5,803)](/filings/0001378325-25-000040.md) | [(4,634) d](/filings/0001378325-26-000010.md) | [(5,382)](/filings/0001378325-26-000021.md) | [(4,651)](/filings/0001378325-26-000036.md) | [(8,019)](/filings/0001378325-25-000040.md) | [(7,464) d](/filings/0001378325-26-000010.md) | [(7,093)](/filings/0001378325-26-000021.md) | [(7,580)](/filings/0001378325-26-000036.md) |
| Income tax | $k | not reported | [0.0](/filings/0001378325-25-000010.md) | [0.0](/filings/0001378325-25-000040.md) | [11.0 d](/filings/0001378325-26-000010.md) | [0.0](/filings/0001378325-26-000021.md) | [0.0](/filings/0001378325-25-000010.md) | [0.0](/filings/0001378325-25-000040.md) | [24.0 d](/filings/0001378325-26-000010.md) | [0.0](/filings/0001378325-26-000021.md) | [0.0](/filings/0001378325-26-000036.md) |
| Net income | $k | [(4,200)](/filings/0001378325-25-000040.md) | [(5,266)](/filings/0001378325-25-000040.md) | [(5,794)](/filings/0001378325-25-000040.md) | [(4,639) d](/filings/0001378325-26-000010.md) | [(5,375)](/filings/0001378325-26-000036.md) | [(4,625)](/filings/0001378325-26-000036.md) | [(7,921)](/filings/0001378325-25-000040.md) | [(7,394) d](/filings/0001378325-26-000010.md) | [(7,033)](/filings/0001378325-26-000036.md) | [(7,481)](/filings/0001378325-26-000036.md) |
| Diluted EPS | $ per share | not reported | [(2.58)](/filings/0001378325-25-000010.md) | [(2.79)](/filings/0001378325-25-000040.md) | not reported | [(2.49)](/filings/0001378325-26-000021.md) | [(2.02)](/filings/0001378325-26-000036.md) | [(0.17)](/filings/0001378325-25-000040.md) | not reported | [(0.15)](/filings/0001378325-26-000021.md) | [(0.15)](/filings/0001378325-26-000036.md) |
| Basic EPS | $ per share | not reported | [(2.58)](/filings/0001378325-25-000010.md) | [(2.79)](/filings/0001378325-25-000040.md) | not reported | [(2.49)](/filings/0001378325-26-000021.md) | [(2.02)](/filings/0001378325-26-000036.md) | [(0.17)](/filings/0001378325-25-000040.md) | not reported | [(0.15)](/filings/0001378325-26-000021.md) | [(0.15)](/filings/0001378325-26-000036.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Current assets | $m | not reported | not reported | not reported | not reported | [14.8](/filings/0001378325-26-000010.md) | not reported | [7.8](/filings/0001378325-25-000010.md) | [24.0](/filings/0001378325-25-000040.md) | [16.7](/filings/0001378325-26-000036.md) | [24.5](/filings/0001378325-26-000021.md) | [17.3](/filings/0001378325-26-000036.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [16.8](/filings/0001378325-26-000010.md) | not reported | [9.5](/filings/0001378325-25-000010.md) | [25.7](/filings/0001378325-25-000040.md) | [18.2](/filings/0001378325-26-000036.md) | [25.9](/filings/0001378325-26-000021.md) | [18.6](/filings/0001378325-26-000036.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [1.8](/filings/0001378325-26-000010.md) | not reported | [4.2](/filings/0001378325-25-000010.md) | [4.6](/filings/0001378325-25-000040.md) | [4.4](/filings/0001378325-26-000036.md) | [5.4](/filings/0001378325-26-000021.md) | [5.2](/filings/0001378325-26-000036.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [2.7](/filings/0001378325-26-000010.md) | not reported | [4.9](/filings/0001378325-25-000010.md) | [5.2](/filings/0001378325-25-000040.md) | [4.9](/filings/0001378325-26-000036.md) | [5.7](/filings/0001378325-26-000021.md) | [5.4](/filings/0001378325-26-000036.md) |
| Shareholders' equity | $m | [(110)](/filings/0001378325-26-000010.md) | [(114)](/filings/0001378325-25-000040.md) | [(119)](/filings/0001378325-25-000040.md) | [(125)](/filings/0001378325-25-000040.md) | [(130)](/filings/0001378325-26-000036.md) | [(135)](/filings/0001378325-26-000036.md) | [(139)](/filings/0001378325-26-000036.md) | [20.4](/filings/0001378325-25-000040.md) | [13.3](/filings/0001378325-26-000036.md) | [20.2](/filings/0001378325-26-000036.md) | [13.2](/filings/0001378325-26-000036.md) |

- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(7,056) d](/filings/0001378325-25-000040.md) | [(5,399) d](/filings/0001378325-26-000010.md) | [(4,986)](/filings/0001378325-26-000021.md) | [(4,526) d](/filings/0001378325-26-000036.md) | [(5,666) d](/filings/0001378325-25-000040.md) | [(7,686) d](/filings/0001378325-26-000010.md) | [(6,066)](/filings/0001378325-26-000021.md) | [(8,403) d](/filings/0001378325-26-000036.md) |
| Capital expenditure | $k | [4.0 d](/filings/0001378325-25-000040.md) | [0.0 d](/filings/0001378325-26-000010.md) | [40.0](/filings/0001378325-26-000021.md) | [30.0 d](/filings/0001378325-26-000036.md) | [12.0 d](/filings/0001378325-25-000040.md) | [8.0 d](/filings/0001378325-26-000010.md) | [48.0](/filings/0001378325-26-000021.md) | [0.0 d](/filings/0001378325-26-000036.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.0](/filings/0001378325-25-000010.md) | [2.1](/filings/0001378325-25-000040.md) | [2.2](/filings/0001378325-26-000021.md) | [2.3](/filings/0001378325-26-000036.md) | [46.2](/filings/0001378325-25-000040.md) | [47.5](/filings/0001378325-26-000021.md) | [49.9](/filings/0001378325-26-000036.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 50,046,913 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001378325-26-000036.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.